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Adipose tissue as a stem cell source is ubiquitously available and has several advantages compared to other sources. It is
easily accessible in large quantities with minimal invasive harvesting procedure, and isolation of adipose-derived mesenchymal
stromal/stemcells(ASCs)yieldsahighamountofstemcells,whichisessentialforstem-cell-basedtherapiesandtissueengineering.
Several studies have provided evidence that ASCs in situ reside in a perivascular niche, whereas the exact localization of ASCs in
native adipose tissue is still under debate. ASCs are isolated by their capacity to adhere to plastic. Nevertheless, recent isolation and
culture techniques lack standardization. Cultured cells are characterized by their expression of characteristic markers and their
capacity to diﬀerentiate into cells from meso-, ecto-, and entodermal lineages. ASCs possess a high plasticity and diﬀerentiate
into various cell types, including adipocytes, osteoblasts, chondrocytes, myocytes, hepatocytes, neural cells, and endothelial and
epithelial cells. Nevertheless, recent studies suggest that ASCs are a heterogeneous mixture of cells containing subpopulations of
stem and more committed progenitor cells. This paper summarizes and discusses the current knowledge of the tissue localization
of ASCs in situ, their characterization and heterogeneity in vitro, and the lack of standardization in isolation and culture methods.
1.Introduction:Mesenchymal
Stromal/Stem Cells
ThepathologistCohnheimﬁrstobservedthepresenceofnon-
hematopoietic stem cells in the bone marrow in 1867 [1]. He
hypothesized that cells with a ﬁbroblast-like morphology
migrate to the sites of injury and help to regenerate damaged
tissue.ThepioneeringworkofFriedensteinandcoworkersin
the 1960s [2, 3] on the isolation, culture, and osteogenic dif-
ferentiationofbone-marrow-derivedcellsopenedanewﬁeld
of stem cell research. Nearly 20 years later, Owen [4]a n dC a -
plan [5] introduced the terms stromal stem cells and mes-
enchymal stem cells (MSCs) to the scientiﬁc community.
Whereas, in these initial works, MSCs were isolated from ad-
ult bone marrow, in the next decades, MSCs were also found
in nearly all adult tissues (e.g., adipose tissue, synovium, der-
mis,periosteum,deciduousteeth),inperipheralblood,men-
strual blood, and in solid organs (e.g., liver, spleen, lung) [6–
8]. MSCs are a rare and quiescent population in their niche
within fully specialized tissues. At present, there is a strong
amount of data indicating that MSCs represent independent
population(s) of stem cells with self-renewal properties and
established multipotent diﬀerentiation proﬁle in vitro [9].
Furthermore, MSCs are attractive candidates for clinical ap-
plications to repair or regenerate damaged tissues, especially
because these cells hold no ethical concerns and can be iso-
lated in appropriate amounts from several sources and pro-
liferated in culture. In addition, MSCs from autologous orig-
inseemtobeasafesourceforcell-basedregenerativeapproa-
ches.
There is also evidence that MSC preparations are hetero-
geneouscellculturescomprisingasubsetofstemcells(ordif-
f e r e n ts u b s et so fs t e mc e ll s )a n dm o r ed i ﬀerentiated (progen-
itor) cells. To address the inconsistency between the nomen-
clature and biologic properties of this heterogeneous popul-
ation, the International Society for Cellular Therapy has sug-
gested that these plastic-adherent cells, regardless of the
tissue from which they are isolated, be termed multipotent
mesenchymal stromal cells, while the term mesenchymal
stem cells should be used only for the subset (or subsets)2 Stem Cells International
that meets speciﬁed stem cell criteria [10]. In general, MSCs
areisolatedbytheircapacitytoadheretoculture-dishplastic.
The cells can be expanded in culture while maintaining their
multipotency during standard cell culture and are immuno-
logically characterized by a speciﬁc panel of markers. How-
ever, the characterization of MSCs remains diﬃcult due to
the lack of a deﬁnitive and unique cellularmarker. Therefore,
the International Society for Cellular Therapy proposed
three minimal criteria for the deﬁnition of cultured MSCs:
(a) plastic adherence, (b) expression of CD73, CD90, and
CD105, and lack of CD11b or CD14, CD 19 or CD79α,
CD45, and HLA-DR expression, and (c) their trilineage dif-
ferentiation potential into adipocytes, chondrocytes, and os-
teoblasts [11]. Furthermore, MSCs have reduced immuno-
genicpropertiesandanimmunosuppressivepotential,which
makethemalsoattractiveforallogenicstemcelltherapy[12–
15]. In addition, ideal MSCs for use in therapeutical ap-
proaches need to be isolated with minimal harm for the pa-
tient, must be available in high cell numbers, proliferate in
culture, and diﬀerentiate into a broad spectrum of lineages.
2. Adipose-DerivedMesenchymal
Stromal/Stem Cells
Over the past ten years, it has been recognized that fat is not
onlyanenergyreservoir,butalsoarichsourceofmultipotent
stem cells. Subcutaneous adipose depots are ubiquitous and
easily accessible in large quantities with a minimal invasive
procedure(byliposuctionaspiration).Liposuctionsurgeryis
a well-tolerated and safe procedure yielding large quantities
of aspirate. The method is cheaper and less invasive than
bonemarrowaspirationforstemcellisolation. Furthermore,
the lipoaspirate is ﬁnally discarded as medical waste, qualify-
ing this starting material as a good source of (autologous)
adipose-derived mesenchymal stromal/stem cells (ASCs) for
furthercellisolation.Nevertheless,itisalsopossibletoisolate
ASCs from needle biopsies of human adipose tissue or from
inguinal fat pads in mice, as well as from other mammals
[16–20].
Adipose tissue contains a large number of multipotent
cells, which is an essential prerequisite for stem-cell-based
therapies.Ithasbeendescribedthatstemandprogenitorcells
in the uncultured stroma-vascular fraction (SVF) from adi-
pose tissue usually amount to up to 3% of the whole cells,
and this is 2,500-fold more than the frequency of stem cells
inbonemarrow[21].Othershavealsodescribedthatadipose
tissueprovideslargenumbersofstemcellscomparedtobone
marrow. A bone marrow transplant contains approximately
6 × 106 nucleated cells per mL [22], of which only 0.001–
0.01% are stem cells [23]. In comparison, the number of
SVF cells that can be isolated from subcutaneous liposuction
aspirates is approximately 0.5–2.0 × 106 cells per gram of
adipose tissue [22, 24–27], whereby the percentages of stem
cells range from 1 to 10% [26, 28, 29], most likely depending
on the donor and tissue harvesting site. Therefore, approx-
imately 0.5 × 104 to 2 × 105 stem cells can be isolated per
gram of adipose tissue, varying among patients.
The isolation method and the cytological characteriza-
tion of stromal precursor cells from adipose tissue were
shown at the beginning of the 1970s [30, 31]. Later, the adi-
pogenic and osteogenic potential of this cell population was
analyzed [32–35]. The work of Zuk and coworkers in 2001
and 2002 ﬁrst characterized the multipotent character of
ASCs [24, 36]. It should be mentioned that a diﬀerent
nomenclature for the isolated cell population was used in
the literature, thus generating a confusing discrepancy. The
terms “adipose-derived adult stem (ADAS) cells,” “adipose-
derived adult stromal cells,” “adipose-derived stromal cells
(ADSC),” “adipose stromal cells (ASC),” “adipose mesen-
chymal stem cells (AdMSC),” “preadipocytes,” “processed
lipoaspirate (PLA) cells,” and “adipose-derived stromal/stem
cells (ASCs)” for cells isolated almost by a similar isolation
procedure (plastic adherence) and, therefore, probably the
same cell population(s) were used in the literature. To elimi-
nate this discrepancy, the International Fat Applied Technol-
ogy Society (IFATS) reached a consensus to adopt the term
“adipose-derived stromal/stem cells” to identify the plastic-
adherent,culturedandseriallypassaged,andmultipotentcell
population from adipose tissue [28, 37].
3. Originof ASCs InSitu
Several studies have tried to identify the location of the stem
cell population within intact adipose tissue. This is a com-
plicated endeavour because no single marker speciﬁcally and
unequivocally identiﬁes undiﬀerentiated ASCs (as well as
MSCs in general). Results from these histological studies
using immunohistochemical and immunoﬂuorescence tech-
niques suggest that a stem cell population (or populations)
resides in a perivascular location, where ASCs coexist with
pericytes and endothelial cells. It has also been suggested
t h a tA S C s( a n dM S C si ng e n e r a l )a r eas u b s e to fp e r i c y t e so r
vascular stem/precursor cells at various stages of diﬀerentia-
tion located in the wall surrounding the vasculature [38]. It
has also been hypothesized that blood vessels in virtually all
organs and tissues harbour ubiquitous (mesenchymal) stem
cells in their perivascular niche [39].
Severalinvestigationsencouragedthehypothesisofaper-
ivascular localization of ASCs. It has been speculated that
ASCs exist as CD34+/CD31−/CD140β−/α-smooth muscle
actin− (smA)cellsincapillariesandintheadventitiaoflarger
vessels [40]. Zimmerlin and coworkers investigated the loca-
lization of known endothelial and perivascular markers in
sections of intact adipose tissue and detected a CD90+/
CD34+/CD31−/CD146−/smA− population in the outer ad-
ventitial ring of the vasculature [41]. They identiﬁed these
cells as supra adventitial ASCs. Traktuev and coworkers de-
scribed that ASCs are primarily located in the walls of adi-
pose microvasculature in a CD34+/CD31− phenotype [42].
Another study of this group described that these cells are
capable of stabilizing endothelial networks in vitro,a sw e l la s
robustly synergizing with endothelial cells to participate in
the in vivo formation of new vessels which connect with host
vasculature, conduct blood ﬂow, and exhibit network stabil-
ity for several weeks [43]. Others described a perivascularStem Cells International 3
cell subset in the smallest blood vessels and adventitial cells
around larger ones, which natively expresses mesenchymal
stem cell markers and displays multilineage diﬀerentiation in
culture [39, 44, 45]. The authors identiﬁed these perivascular
cells by their expression of CD146, neuroglial proteoglycan 2
(NG2), and CD140β, in addition to standard MSC markers
(CD44, CD73, CD90, CD105). Nevertheless, the cell subset
described did not express CD34. In addition, others des-
cribed CD146+ cells in the perivascular region that exhibit
the biological properties of MSCs if isolated and cultured
[46]. Therefore, due to the expression of CD146, these cells
are clearly distinct from the cells described by Lin, Zimmer-
lin, and Traktuev. There is also another recent work, in con-
trast to these studies, which described that only the smA+
cells from murine adipose tissue display a multilineage dif-
ferentiation potential, while smA− cells only diﬀerentiate in-
to adipocytes in vitro [47].
Whereas all these studies provided much evidence and it
seems likely that ASCs in situ reside in a perivascular niche
in a CD34+/CD90+/CD31−/CD45−/CD146− phenotype, the
deﬁnite identiﬁcation of the ASC population(s) in situ has
currently not been achieved. The niche (local microenviron-
ment) is a crucial determinant not only of stem cell fate,
function, and maintenance, but maybe also of the ASCs’
phenotype.
4. Characterizationof Uncultured
PrimaryIsolates
ASCs can easily be isolated by tissue digestion and cen-
trifugation steps, followed by the outgrowth of the plastic
adherent fraction from the primary isolated cell mixture
(the so-called SVF) [24]. SVF is a highly heterogeneous cell
population, because it also comprises the nonadherent cell
population. The composition of the SVF has been reported
with great variability among authors. Cell populations with-
in the SVF could be roughly distinguished by cell size and
granularity in ﬂow cytometry by forward and sideward
scatter diagrams and by their characteristic expression pat-
tern. Miranville and coworkers described some stem cell ma-
rkers (CD34, CD133, ABCG2) in the SVF from diﬀerent an-
atomic sources. They ﬁrst described that freshly harvested
SVF contains large numbers of CD34+ cells and showed
two subpopulations of CD34+ cells [48]. A more compre-
hensive characterization was done by Yoshimura and co-
workers. They identiﬁed cell populations in the SVF in-
cluding the following potential ASCs (CD31−/CD34+/
CD45−/CD90+/CD105−/CD146−), endothelial (progenitor)
cells(CD31+/CD34+/CD45−/CD90+/CD105low/CD146+),pe-
ricytes (CD31−/CD34−/CD45−/CD90+/CD105−/CD146+),
and blood-derived cells (CD45+) by multicolour ﬂow cyto-
metric analysis [49] ,w h e r e a si ti sm o s tl i k e l yt h a ta l s o
ﬁbroblasts, vascular smooth muscle cells, and preadipocytes
are present in the SVF. It has also been described that the
S V Fi sc o m p o s e do f1 1 %C D 2 + cells, 18% CD11a+ cells, 29%
CD14+ cells, 49% CD31+ cells, 57% CD45+ cells, and 60%
CD90+ cells (referring to ASCs and endothelial cells) [50].
Others detected a diﬀerent composition of the SVF (nearly
11% CD14+ cells, ∼2% CD31+ cells, ∼7% CD34+, ∼9%
CD45+ cells, ∼29% CD90+,a n d∼47% 146+ cells) [51].
It has been demonstrated that more than 85% of the
SVF cells that initially adhered to the culture wells had
a CD31−/CD34+/CD45−/CD146− phenotype [52]. Within
the CD34+ cells, two subpopulations with diﬀerent phe-
notypes have been identiﬁed (a CD34dim and CD34bright
subpopulation) [51]. In addition, it has been described
that the CD31−/CD34+/CD45−/CD105+ cells from puriﬁed
uncultured adipose tissue display stem cell properties [53].
The authors also compared CD31− and CD31+ cells from
the SVF and showed that only the CD31− subpopulation
displayed multilineage diﬀerentiation in vitro. Nevertheless,
thedatacurrentlyavailableareinconsistentandnotadequate
for the clear deﬁnition of an exclusive ASCs population in
the SVF. Sharing membrane antigens with other cells found
in the SVF, ASCs could not be deﬁnitely distinguished in
the whole heterogeneous SVF cell mixture. This is indeed
also based on two facts: (1) that there are several stem cell
subpopulations within the SVF and (2) that the cells are
relatedtotheplasticadherentandculturedpopulationwhich
dramatically changes the phenotype very early during cell
culture.
5. Characterization andHeterogeneity
of CulturedASCs
The fraction of adherent cells cultured in standard cell cul-
ture medium is considered as multipotent ASCs. The cells of
this fraction are characterized early during primary culture
by a slightly heterogeneous morphology indicating diﬀerent
stem and precursor cell subpopulations and (maybe) more
diﬀerentiatedcells(dediﬀerentiatedendothelialcells,smooth
muscle cells, and pericytes). Heterogeneity of MSC isolations
in general has been discussed in many publications [54–57].
Nevertheless, when analyzing the adherent population by
ﬂow cytometry, no macrophages, endothelial cells, lympho-
cytes, or granulocytes seem to remain [50]: for example, the
presence of endothelial cells is not detectable [50]. However,
endothelial cells in culture are extremely susceptible to
culture conditions, such as supplements and particularly
shear stress, and, therefore, may dediﬀerentiate or trigger
apoptosis under static culture conditions [57].
The heterogeneity of cultured ASCs can be reduced by a
washing procedure early in the beginning of the cell culture
[58], indicating that several subsets require diﬀerent time
points to adhere to the cell culture plastic. Other eﬀorts
to reduce the heterogeneity or to isolate speciﬁc subsets
of ASCs were carried out by using ﬂow cytometric sorting
or immunomagnetic separation, either by positive or by
negative selection [59–62]. The usage of such techniques for
the reduction of heterogeneity is more or less beneﬁcial but
leads to a very small cell yield. By using immunomagnetic
beads, Rada and coworkers demonstrated that the SVF is
composed of several subpopulations, which express diﬀerent
levels of ASC markers and exhibit varying osteogenic and
chondrogenic diﬀerentiation potentials [60].4 Stem Cells International
Cultured ASCs show an extensive proliferative ability in
an uncommitted state while retaining their multilineage dif-
ferentiation potential. In later passages, ASC cultures are
homogeneous and exhibit a ﬁbroblastoid morphology. The
composition of subpopulations, therefore, may change dur-
ing expansion [63]. Cell cultureselectsforthishomogeneous
morphology, enriching for cells expressing a stromal im-
munophenotype [28]. Diﬀerent studies have characterized
and compared the immunophenotype of cultured ASCs in
earlyandlaterpassagesoverthepastfewyearsandfoundthat
theexpressionproﬁleofASCschangesduringculturetime.It
has been repeatedly shown that freshly isolated ASCs express
diﬀerent surface markers than ASCs in higher passages [28,
52]. At the beginning of the culture, ASCs do not uni-
formly express all surface proteins, which are supposed to
be characteristic. Subsets with distinct phenotypic properties
can be discerned in freshly isolated cells by speciﬁc surface
markers [63]. On the other hand, ASCs in passage 2 or 3
uniformly express their characteristic markers (positive for
CD10, CD13, CD29, CD 44, CD49e, CD73, CD90, CD105,
and CD166, and negative for CD11b, CD14, CD31, and
HLA-DR) [35]. The expression of the markers seems to be
dependent on culture conditions or time in culture. The
speciﬁc surface markers CD29, CD90, and CD166 increase
during culture [28], while the expression of other markers
decreases [28, 52] .S i m i l a rt oS V Fa n dc o n t r a r yt ol o n g -
term cultured ASCs, freshly isolated ASCs are described as
expressing CD34, CD117, and HLA-DR [52]. In the case
of CD34, it has been demonstrated that more than 95% of
the cells are still CD34 positive after one week of culture,
whereas, subsequently, the expression level of CD34 de-
creases dramatically during culture. It has also been des-
cribed that only some ASCs lose their CD34 expression with
increasing culture time and that cell culture in medium 199
supplemented with acidic FGF maintained CD34 expression
for at least 10–20 weeks [49]. On the other hand, expression
of CD105 and especially CD166 is relatively low on the
freshly isolated ASCs but rises to a high extent during cell
culture [52]. Another study also described that stromal cell-
associated markers (CD29, CD73, CD166) are initially exp-
ressed lower but rise during successive passages, whereas the
expression of CD34 dramatically decreases [28].
Whereas expression of some characteristic markers is
consistentlyfoundtobeexpressedbyculturedASCsandoth-
ers are consistently not found to be expressed (summarized
in[64]),manystudiesdiﬀerinsomeofthemarkers.Theexp-
ression of some antigens is described in a very contrary way.
Some reports described CD34, CD54, CD107, or CD146 to
be expressed on cultured ASCs, and others did not ﬁnd the
expressionoftheseantigens.Thesediﬀeringresultsaredueto
diﬀerences in the isolation or culture method or caused by
the investigation of diﬀerent passages of cultured ASCs: for
example, although CD34 is reckoned as a hematopoietic
stem-cell-associated marker, it is expressed by early passages
of ASCs’ subsets and subsequently lost in later passages [28,
49]. Another study compared the CD34+ and CD34− subsets
of ASCs and found that CD34+ cells are more proliferative
and have a higher ability to form colonies, while CD34− cells
have a greater ability to diﬀerentiate into adipogenic and
osteogenic lineages [65]. CD34+ cells also expressed other
endothelial markers, whereas CD34− cells expressed markers
such as CD146. CD146 is described as lowly expressed by the
whole ASCs population, and this expression decreases with
culture time [28]. Since CD146 is also a marker for endo-
thelial cells and pericytes, it could belong to a subset of ASCs
[26, 49]. Taken together, comprehensive studies are needed
to further characterize the whole expression proﬁle of ASCs
in diﬀerent passages in detail.
6. What about Standardization of the Isolation
andCultureProcedure?
Discrepancies in the results of studies from diﬀerent labo-
ratories may result from many diﬀerent origins. First of all,
ASCs are isolated from diﬀerent donors. These donors diﬀer
in age, body mass index, gender, ethnicity, and their medical
history (e.g., preexisting diseases, nicotine, or alcohol abuse
in humans). It has been shown, for example, that the body
mass index correlates negatively to the number of stromal
cells per gram and their diﬀerentiation capacity [66]. The
liposuction procedure may diﬀer between diﬀerent clinics,
the liposuction (or biopsy) side is diﬀerent, and the time la-
pse until isolation procedure starts diﬀers between the lab-
oratories.Ithasbeenreported forASCsthatliposuctionside,
liposuction procedure, age, or body mass index play an im-
portant role in the cell yield, growth, and frequency of stem
cells [26, 66–69], but it is not clear whether this favours dif-
ferent subsets in cultured ASCs. All these variables may aﬀect
the composition of the isolated initial cell culture, but it is
extremely diﬃcult, if not impossible, to standardize these
variables.
On the other hand, the methods and quality of isolations
ofASCsfromdiﬀerentlaboratoriespersevarytremendously,
resulting in a diﬀerent composition of the initial cell cul-
ture. Finally, the culture procedure of isolated ASCs diﬀers
between the laboratories; at the present time, there is no
unique and standardized culture protocol for the culture of
ASCs. There are many variables that impair the cultured cells
(or the composition of subpopulations) in their undiﬀeren-
tiated state: initial plating density and conﬂuency, coating
of culture dishes and stiﬀness of the substrate, composition
of cell culture basal media, cell culture supplements (bovine
serum, human serum, platelet lysate, or growth factors), ad-
dition of antibiotics, oxygen supply (hypoxia), and method
of subculturing and cryopreservation (Table 1).
In vivo, many cell types are attached to soft materials,
eitherothercellsorextracellularmatrices,butmostofwhatis
knownaboutcellstructureandfunctioninvitroderivesfrom
studies of cells plated onto rigid substrates, such as plastic
[70]. As a result, some aspects found in vitro are rarely if ever
seen in vivo [70]. Diﬀerentiation of MSCs, for example, has
been shown to be dependent on the substrate on which
the cells are cultured. Whereas MSCs on stiﬀ substrates
expressed markers of osteogenesis, MSCs on softer substrates
expressedmyogenicmarkers,andcellsonthesoftestgelsexp-
ressed neuronal markers [71]. Nevertheless, stiﬀness alone
is not suﬃcient to fully diﬀerentiate cells. Furthermore,Stem Cells International 5
Table 1: Summary of cell culture parameters which aﬀect the
undiﬀerentiated state of ASCs.
(i) Basal medium
→ Medium composition (e.g., DMEM,
αMEM, M199)
→ Glucose content
→ Calcium content
(ii) Supplements
→ Serum (bovine or human)
→ Platelet lysate
→ Growth factors (e.g., bFGF, aFGF, EGF,
PDGF)
→ Corticoids
→ Antioxidants
→ Antibiotics (?)
(iii) Environment
→ Hypoxia
→ Perfusion culture (Shear stress)
→ Stiﬀness of the substrate (coating)
→ Mechanical strain
→ Conﬂuency (cell cell-contacts)
the inﬂuence of plastic coating with collagen or ﬁbronectin
has also been shown to inﬂuence the diﬀerentiation state of
MSCs [72]. Therefore, more work about the optimal sub-
strate and substrate stiﬀness to culture ASCs is highly des-
irable.
Only limited information is available about which me-
dium optimally expands ASCs by maintaining the undif-
ferentiated stem cell character in vitro [73–75]. It has been
shown in cultures of MSCs that basal medium, glucose con-
centration,qualityofFCS,cellplating,andcelldensityhighly
aﬀect the ﬁnal outcome [76], resulting in the expansion of
populations with totally diﬀerent potential. The media com-
position, for example, highly eﬀects the expression of the
stem-cell-related transcription factors NANOG, Oct-4, Sox-
2, and Rex-1 in ASCs [75]. These factors have also been
shown to be expressed by ASCs in earlier studies [27, 77, 78]
andarerelatedtotheundiﬀerentiatedstateofASCs(andalso
to pluripotency of stem cells in general). Many laboratories
use Dulbecco’s modiﬁed Eagle medium (DMEM) as a basal
medium to culture ASCs, but there are diﬀerent DMEMs
commerciallyavailable,andafurtherdescriptionoftheexact
medium used in these studies is often not indicated. We use
DMEM with an approximately physiological glucose content
(100mg/dL). Others use a standard DMEM with a higher
glucosecontent,because,inthismedium,ASCsshowamuch
better proliferation rate. Nevertheless, a physiological glu-
cose content is one variable which should be considered to
be near to the in vivo situation. Furthermore, a low calcium
concentration and supplementation with antioxidants have
beenshowntoacceleratetheproliferationofASCs,butitwas
not clearly shown that this culture medium did not alter the
whole diﬀerentiation capacity of ASCs [79].
Most of the investigators use DMEM with 10% foetal calf
or bovine serum as a standard proliferation medium, where-
as others use low-serum expansion media supplemented
with one or more growth factors, for example, epidermal
growth factor (EGF), platelet-derived growth factor, and/or
basic ﬁbroblast growth factor [80–83]. There are many
concerns about the practicability of foetal calf or bovine
serum (infectious complications, host immune reactions)
related to a possible use of ASCs in human therapeutical ap-
proaches [84]. Additionally, human serum may be a source
of pathogen contamination or immunoreactivity and shows
batch-to-batchvariability.Usingdeﬁnedcellculturemedium
is an urgent need in order to produce ASCs for clinical ap-
plications. The gold standard for culturing ASCs would be a
medium absolutely free of animal serum or factors, with
well-known ingredients. Parker and coworkers tested eight
commercially available serum-free media developed for use
with other cell lines for their ability to support growth of
human ASCs [74]. None of the available media was suﬃcient
for supporting cell growth as purchased, and none per-
formed better as a base medium than their standard medium
containing serum. Others described serial testing of new me-
dium formulations containing human serum or platelet ly-
sateortestedtheuseofanimalserum-orxeno-freemediafor
the culture of ASCs in regard to cell morphology, cell pro-
liferation, phenotype, and diﬀerentiation potential [85–88].
As a result of these studies, there is obviously no favourable
serum- and xeno-free medium for the expansion of ASCs
retaining their undiﬀerentiated state. Rajala and coworkers,
for example, described a xeno-free medium that induced sig-
niﬁcantly higher proliferation rates than medium containing
allogeneic human serum [88]. This medium maintained the
diﬀerentiation potential of ASCs. Nevertheless, the authors
detected signiﬁcant diﬀerences in the surface marker expres-
sion of ASCs cultured in xeno-free medium compared with
human serum.
In summary, modiﬁcations in the isolation and/or cul-
ture conditions might select for the expansion of subpop-
ulations and have a huge impact on the diﬀerentiation po-
tential of the cells cultured, albeit the primary cells could be
phenotypically identical [57]. Therefore, standardization of
the isolation and culture procedure is highly needed for a
good reproducibility of results from diﬀerent laboratories
and studies.
7. The DifferentiationPotentialof ASCs
The in vitro diﬀerentiation of ASCs into multiple cell types
of mesodermal origin has been shown in a variety of studies.
ASCs can be cultured by serial passaging without losing their
multipotent properties [27] and have the capacity to main-
tain chromosome stability in long-term cultures [89]. Diﬀer-
ent studies described ASCs’ plasticity towards chondrocytes,
osteoblasts, adipocytes, and myocytes (cardiomyocytes,
smooth muscle, and skeletal muscle cells) [24, 36, 90–97]. In
general, the induction of ASCs’ diﬀerentiation in vitro is
mainly achieved by culture in selective media with lineage-
speciﬁc induction factors. The transcriptional and molecular
events triggering the mesodermal lineage-speciﬁc diﬀerenti-
ation of stem cells are well known [98–103]. ASCs have also
been shown to be angiogenic and hematopoietic supporting
cells [104–106]. These supporting characteristics of ASCs are6 Stem Cells International
mainly due to the secretion of antiapoptotic angiogenic and
hematopoietic factors (cytokines and growth factors), such
as macrophage colony-stimulating factor, granulocyte ma-
crophage colony-stimulating factor, insulin-like growth fac-
tor, hepatocyte growth factor, vascular endothelial growth
factor, hepatocyte growth factor, and transforming growth
factor-β [107–109].
The potential of ASCs to diﬀerentiate into lineages with
nonmesodermal origin, although ASCs originate from the
mesoderm, is even more exciting. The diﬀerentiation poten-
tialofASCsintocellsofecto-andendodermaloriginhasalso
been shown. Therefore, the term pluripotent stem cells
wouldbemorecorrectforASCs(ratherthanmultipotent),as
ad i ﬀerentiation into cells from all three germ layers has been
shown. Nevertheless, the morphology of ASCs is diﬀerent
to other pluripotent stem cells, and their ability to form
teratomahasnotbeenshown.Therefore,ASCs’pluripotency
is not accepted overall in the scientiﬁc community.
A variety of studies documented the induced in vitro
diﬀerentiation into hepatocytes, pancreatic islet cells, neural
cells, endothelial cells, and epithelial cells [16, 50, 75, 110–
120]. Our studies have clearly veriﬁed that ASCs can enter
the epithelial lineage when treated with retinoids [50], con-
ditioned medium(CM)fromrenaltubularepithelial cells,or
amixtureofgrowthfactors[116–119].In vivo diﬀerentiation
of ASCs toward renal epithelial cells has also been shown in
a renal ischaemia-reperfusion model [120]. The multiorgan
engraftment of transplanted ASCs has been shown, in com-
bination with epithelial lineage diﬀerentiation [121]. Fang
and coworkers examined the in vivo characteristics and be-
haviour of human ASCs transplanted in sublethally irradi-
ated nonobese mice with diabetes or severe combined im-
munodeﬁciency. They demonstrated that ASCs diﬀerentiate
into epithelial cells of the gastrointestinal tract, liver, and
bronchi, and endothelial cells by using immunoﬂuorescence
staining and in situ hybridization.
The multilineage potential of ASCs has also been shown
at the single cell level [29, 95, 122]. Clonal analysis of sin-
gle-cell-derived colonies of MSCs demonstrated that not
every cell possesses a trilineage diﬀerentiation potential [63,
123]. This is also the case in single cell clones from human
ASCs, which were induced for adipogenesis, osteogenesis,
chondrogenesis, and neurogenesis using lineage-speciﬁc dif-
ferentiationmedia[29].Eighty-one percentoftheclonesdif-
ferentiated into at least one of the lineages, and 52% of the
clones diﬀerentiated into two or more of the lineages. The
authors, therefore, reasoned that ASCs are a type of multi-
potent adult stem cell and not solely a mixed population of
unipotent progenitor cells [29]. It has been demonstrated
that single clones of ASCs isolated from mouse inguinal fat
pads are capable of clonogenic, myogenic, adipogenic, and
neurogenic diﬀerentiation [122].
Several tissue engineering and cell therapeutical ap-
proaches using ASCs with or without scaﬀolds have been
carried out in animal experiments to verify ASCs’ in vitro
diﬀerentiation potential. Besides the obvious applications of
ASCs to repair or regenerate cartilage, bone, muscle, or adi-
pose tissue, the possibility of peripheral nerve regeneration,
hepatic regeneration, insulin-producing islet cell regenera-
tion,functionalrepairofmyocardialinfarction,andrecovery
of renal function has recently been shown in in vivo models
[124–130]. In most of these in vivo studies, undiﬀerentia-
ted ASCs proliferated under conditions preserving the un-
diﬀerentiated state were transplanted or used to assemble
tissue engineered constructs. Nevertheless, some researchers
used ASCs prediﬀerentiated in culture [131]o rg e n e t i c a l l y
modiﬁed ASCs in their in vivo models [129, 132, 133].
8. FinalRemarks
Apart from all the proven basic scientiﬁc evidence in in vitro
and in vivo studies which have been accumulated during the
last few years, we are at the beginning of a new era of stem
cell therapy. ASCs are probably one of the most powerful
adult stem cells. Both preclinical studies and clinical trials
using ASCs have been initiated for autologous or allogenic
therapeutical trials (recently reviewed in [134]). Neverthe-
less, the lack of standardization in the isolation methods and
culture protocols needs to be overcome in order to eliminate
the signiﬁcant variability in cell quality. Research progress
has also been hampered by the limited knowledge of ASCs’
subsets, due to the lack of unique markers for their isolation.
In addition, good manufacturing practices (GMP), qualiﬁed
isolation, and culture protocols are needed for the use of
ASCs in clinical trials [135, 136]. A variety of other questions
need to be answered before ASCs can be used in standard
clinical usages: bio-safety (tumour capacity), reproducibility,
and eﬃciency of transplanted ASCs. Moreover, additional
studies using in vivo models are needed to augment our
understanding of how the migration, growth, and diﬀeren-
tiation of ASCs are governed by interactions with resident
cells, growth factors, and cytokines during regeneration or
repair. Nevertheless, the entirety of recent in vivo studies and
ofthefewpublishedcasereportsandclinicaltrialshasshown
that ASCs are on the direct path to their clinical usage for the
treatment of a multitude of diseases.
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